Atea Pharmaceuticals (AVIR) · bemnifosbuvir + ruzasvir
Later window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: March 2027
we currently anticipate submitting an NDA to the FDA in March 2027
· filed · SEC filing
After
Stated timing: second quarter of 2027
Following the recent topline readout for C-BEYOND and pending results from C-FORWARD, Atea anticipates submitting a new drug application (NDA) to the US Food & Drug Administration (FDA) in the second quarter of 2027.
SEC original · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/AVIR-bemnifosbuvir-ruzasvir-2026-08-12, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/AVIR-bemnifosbuvir-ruzasvir-2026-08-12
Atea Pharmaceuticals (AVIR) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-K is a company’s annual report to the SEC, with audited financial statements.